Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt - PubMed (original) (raw)

doi: 10.1038/nm.3908. Epub 2015 Jun 24.

Alex S Petrucelli 1, Liang Chen 1, A Alicia Koblansky 1, Agnieszka D Truax 1, Yoshitaka Oyama 1, Arlin B Rogers 2, W June Brickey 1, Yuli Wang 3, Monika Schneider 4, Marcus Mühlbauer 5, Wei-Chun Chou 1, Brianne R Barker 6, Christian Jobin 5, Nancy L Allbritton 3, Dale A Ramsden 7, Beckley K Davis 8, Jenny P Y Ting 1

Affiliations

Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt

Justin E Wilson et al. Nat Med. 2015 Aug.

Abstract

The inflammasome activates caspase-1 and the release of interleukin-1β (IL-1β) and IL-18, and several inflammasomes protect against intestinal inflammation and colitis-associated colon cancer (CAC) in animal models. The absent in melanoma 2 (AIM2) inflammasome is activated by double-stranded DNA, and AIM2 expression is reduced in several types of cancer, but the mechanism by which AIM2 restricts tumor growth remains unclear. We found that Aim2-deficient mice had greater tumor load than Asc-deficient mice in the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colorectal cancer. Tumor burden was also higher in Aim2(-/-)/Apc(Min/+) than in APC(Min/+) mice. The effects of AIM2 on CAC were independent of inflammasome activation and IL-1β and were primarily mediated by a non-bone marrow source of AIM2. In resting cells, AIM2 physically interacted with and limited activation of DNA-dependent protein kinase (DNA-PK), a PI3K-related family member that promotes Akt phosphorylation, whereas loss of AIM2 promoted DNA-PK-mediated Akt activation. AIM2 reduced Akt activation and tumor burden in colorectal cancer models, while an Akt inhibitor reduced tumor load in Aim2(-/-) mice. These findings suggest that Akt inhibitors could be used to treat AIM2-deficient human cancers.

PubMed Disclaimer

Figures

Figure 1

Figure 1

AIM2 is distinct from ASC during colitis-associated colon cancer. (a) Induction procedure for the AOM/DSS model of CAC. (b–d) Weight loss (b), % survival (d, days) (c) and average clinical scores (d) in _Aim2_−/− (n = 25), _Asc_−/− (n = 11) and wild-type (n = 30) mice following induction of CAC using AOM/DSS. Mock wild-type animals (n = 10) received a single i.p. injection of AOM and were given regular drinking water instead of DSS. Error bars, s.e.m. (e) H&E staining of colons from AOM/DSS-treated wild-type, _Aim2_−/− and _Asc_−/− mice and (f) semiquantitative scoring of inflammation in colons from AOM/DSS-treated wild-type and _Aim2_−/− mice (n = 6 for WT AOM/Mock and _Aim2_−/− AOM/DSS, and n = 5 for WT AOM/DSS and _Aim2_−/− AOM/Mock). Images were taken at 200× magnification; scale bars, 100 µm. (g) Inflammatory cytokine mRNA (AU, arbitrary units) (n = 3 for WT AOM/Mock and _Aim2_−/− AOM/Mock, and n = 6 for WT AOM/DSS and _Aim2_−/− AOM/DSS) and (h) protein expression in wild-type and _Aim2_−/− colons (n = 5 for WT AOM/Mock and _Aim2_−/− AOM/Mock, n = 10 for WT AOM/DSS and n = 8 for _Aim2_−/− AOM/DSS). (i) Caspase-1 activation in wild-type and _Aim2_−/− colons and (j) IL-1β and IL-18 production in wild-type, _Aim2_−/− and _Asc_−/− colons (n = 5 for WT AOM/Mock, _Aim2_−/− AOM/Mock and _Asc_−/− AOM/Mock, and n = 10 for WT AOM/DSS, n = 8 for _Aim2_−/− AOM/DSS and n = 5 for _Asc_−/− AOM/DSS). Error bars, s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001; b,d,j, one-way ANOVA (Tukey's multiple-comparisons test); c, log-rank test.

Figure 2

Figure 2

AIM2 protects against colon tumorigenesis. (a,b) Mini-endoscopy (a) and representative images (b) of colons from AOM/DSS-treated wild-type (n = 5), _Asc_−/− (n = 3) and _Aim2_−/− mice (n = 5). (c) Macroscopic polyp counts, average polyp size per mouse and tumor load (n = 21 for WT, n = 18 for _Aim2_−/− and n = 10 for _Asc_−/−). (d,e) Semiquantitative scoring of colon hyperplasia (d) and dysplasia (e) in AOM/DSS-treated wild-type and _Aim2_−/− mice (n = 6 for WT AOM/Mock and _Aim2_−/− AOM/DSS, and n = 5 for WT AOM/DSS and _Aim2_−/− AOM/Mock). (f) Colon polyp counts, average polyp size per mouse and tumor load in AOM/DSS-treated wild-type, _Aim2_−/−, _Il1b_−/− and _Aim2_−/−/_Il1b_−/− mice, with representative images of colons in the right panel (n = 5 for wild-type, _Aim2_−/− and _Il1b_−/−, and n = 4 for _Aim2_−/−/_Il1b_−/−). (g) Colon polyp counts, average polyp size per mouse and tumor load in AOM/DSS-treated wild-type and _Aim2_−/− radiation bone marrow chimeras, with representative images of colons in the right panel (n = 4 for WT>WT, n = 5 for WT>_Aim2_−/− and n = 7 for _Aim2_−/−>WT and _Aim2_−/−>_Aim2_−/−). (h) Colon polyp counts, average polyp size per mouse and tumor load in _Apc_Min/+ and _Aim2_−/−/_Apc_Min/+ mice representative images of colons in the right panel (n = 6 mice/group). Each symbol represents one animal. Error bars, s.e.m. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001; c,g, one-way ANOVA (Tukey's multiple-comparisons test); d,e,f,h, unpaired _t_-test.

Figure 3

Figure 3

AIM2 negatively regulates Akt activity in vitro and in vivo. (a,b) Western blot analyses of PI3K pathway members in the colons of AOM/DSS-treated mice (representative of n = 6 mice/group). (c) Western blot analyses of Akt phosphorylation in colon homogenates from 12-week-old _Apc_Min/+ and _Aim2_−/−/_Apc_Min/+ mice (representative of n = 6 mice/group). (d–g) Western blot analyses of Akt phosphorylation in IGF-1–simulated MEFs from Aim2+/+ and _Aim2_−/− littermates (d), Asc+/+ and _Asc_−/− littermates (e), AIM2–3xFlag- or EV-transfected HCT-116 cells (f), and wild-type and _Aim2_−/− organoids (g). Actin (

β-actin

) and total Akt were used as loading controls. Results are representative of 1 of 3 experiments.

Figure 4

Figure 4

AIM2 restricts cell proliferation and promotes apoptosis. (a) Colon Ki-67 staining in AOM/DSS-treated wild-type and _Aim2_−/− mice (n = 6 for WT AOM/Mock and _Aim2_−/− AOM/DSS, and n = 5 for WT AOM/DSS and _Aim2_−/− AOM/Mock). 200× magnification; scale bars, 100 µm; error bars, s.e.m. (b) Cell numbers of Aim2+/+ and _Aim2_−/− MEFs (d, days). Error bars, s.e.m., from triplicate samples per group. (c) Western blot analyses of activated caspase-7 and procaspase-7 in colons from AOM/DSS-treated wild-type and _Aim2_−/− mice (n = 6 mice/group). (d) Western blot analyses of activated caspase-3 and procaspase-3 in staurosporine (Staur)-treated Aim2+/+ and _Aim2_−/− MEFs (h, hours). Results are representative of 1 of 3 experiments. (e) Representative images of colons from DMSO- or Akt inhibitor (API-2)-treated _Aim2_−/− mice. (f) Number of macroscopic colon polyps, average polyp size and tumor load in API-2-treated _Aim2_−/− mice. Each symbol represents one animal. Error bars denote standard error. ns, not significant. *P < 0.05, **P < 0.01, ***P < 0.001. a,b, unpaired _t_-test; f, Mann-Whitney _U_-test (due to the non-normal distribution of the data sets and small sample size).

Figure 5

Figure 5

AIM2 associates with DNA-PK and restricts its activity and Akt phosphorylation. (a) Immunoprecipitation of AIM2 and immunoblots of PI3K members and (b) reciprocal immunoprecipitation of DNA-PKcs and immunoblot of AIM2 in AIM2-Flag (Fg)- or empty vector (EV)-expressing HEK293T cells treated with IGF-1 (IGF) (c) Co-immunoprecipitation of DNA-PKcs and AIM2 in the presence of ethidium bromide (EtBr) in HEK293T cells. (d) Western blot analysis of phosphorylated DNA-PK (p-DNA-PK) in bleocin-treated AIM2-expressing HCT-116 cells. (e) Western blot analysis of p-Akt in 10 µM NU7026- or NU7441-treated Aim2+/+ and _Aim2_−/− MEFs. (f) Western blot analysis of activated caspase-3 in staurosporine (Stauro)-treated Aim2+/+ and _Aim2_−/− MEFs treated with NU7026 (5 µM; h, hours). (g) Cell number of Aim2+/+ and _Aim2_−/− MEFs cultured with 1 µM NU7026 (d, days). Error bars, s.e.m., from triplicate samples per group. Results are representative of 1 of 3 independent experiments (a,b,c,d,e,g) and representative of 1 of 2 independent experiments (f). **P < 0.01, ***P < 0.001. One-way ANOVA (Tukey's multiple-comparisons test).

Similar articles

Cited by

References

    1. Weir HK, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst. 2003;95:1276–1299. - PubMed
    1. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 2009;1:a000141. - PMC - PubMed
    1. Hugot JP, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599–603. - PubMed
    1. Ogura Y, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603–606. - PubMed
    1. Dupaul-Chicoine J, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity. 2010;32:367–378. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources